Collectively, these clinical data established a strong association of PPP2R2B expression with clinical outcome of HER2+ breast cancer and suggested a potential role for PPP2R2B in determining the sensitivity of anti-HER2 therapies. Here, ERBB2 is linked to breast carcinoma.